CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 33 enrolled
Drug / intervention
HGP0904 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02387554
NCT02387554Phase 1Completed
CompareCT.gov

A Randomized, Open-label, 4-way Crossover Single Dose Clinical Trial to Investigate the Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405 When Administered Alone and in Combination in Healthy Male Volunteers

Hanmi Pharmaceutical Company Limited·interventional·Posted Mar 13, 2015·Updated Jun 12, 2015

In Brief

A Phase 1 clinical trial evaluating HGP0904, HGP0608, and 1 other intervention for Hypertension(HTN). Completed, enrolled 33 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the pharmacokinetic interaction and safety between HGP0904, HGP0608 and HGP1405 when administered alone and in combination in healthy male volunteers

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension(HTN)
CountriesSouth Korea
CollaboratorsSeoul National University Bundang Hospital

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 13, 2015
Enrollment StartAug 1, 2014
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 11.3 years ago

Interventions

HGP0904drug

HGP0608drug

HGP1405drug